Cargando…

Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan

BACKGROUND: This post-marketing surveillance (PMS) study evaluated the safety and effectiveness of long-term darbepoetin alfa (darbepoetin) for the treatment of renal anemia in Japanese non-dialysis chronic kidney disease patients. METHODS: Patients were treated with darbepoetin and followed up for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Tetsuhiro, Nangaku, Masaomi, Imai, Enyu, Tsubakihara, Yoshiharu, Kamai, Masatoshi, Wada, Michihito, Asada, Shinji, Akizawa, Tadao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510805/ https://www.ncbi.nlm.nih.gov/pubmed/30182223 http://dx.doi.org/10.1007/s10157-018-1632-9

Ejemplares similares

Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan
por: Hayashi, Terumasa, et al.
Publicado: (2020)

Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial
por: Maruyama, Shoichi, et al.
Publicado: (2023)

Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
por: Kato, Hideki, et al.
Publicado: (2017)

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020)

Extended dosing of darbepoetin alfa in peritoneal dialysis patients
por: Feriani, Mariano, et al.
Publicado: (2011)

Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study
por: Narita, Ichiei, et al.
Publicado: (2022)

Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study
por: Kikuchi, Kan, et al.
Publicado: (2021)

Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia
por: Wauters, Isabelle, et al.
Publicado: (2006)

Acute onset anterior uveitis after darbepoetin alfa infusion
por: Li, Jonathan, et al.
Publicado: (2015)

A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study
por: Akizawa, Tadao, et al.
Publicado: (2021)

Understanding Measurements of Vitality in Patients with Chronic Kidney Disease: Connecting a Quality-of-Life Scale to Daily Activities
por: Fukuhara, Shunichi, et al.
Publicado: (2012)

Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin
por: Sepah, Yasir J., et al.
Publicado: (2022)

Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2022)

Two long‐term phase 3 studies of enarodustat (JTZ‐951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND‐Long and HD‐Long studies
por: Akizawa, Tadao, et al.
Publicado: (2021)

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014)

Iron status and erythropoiesis response to darbepoetin alfa in dogs with chronic kidney disease
por: BHAMARASUTA, Chayanont, et al.
Publicado: (2021)

Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations
por: Carrera, Fernando, et al.
Publicado: (2009)

Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study
por: Schaefer, Franz, et al.
Publicado: (2015)

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents
por: Lee, Sung-Eun, et al.
Publicado: (2018)

Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers
por: Kim, Seokuee, et al.
Publicado: (2018)

Acquired Pure Red Cell Aplasia Following Recombinant Erythropoietin (Darbepoetin-alfa) Therapy
por: Padhi, Somanath, et al.
Publicado: (2020)

Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study
por: Galle, Jan-Christoph, et al.
Publicado: (2016)

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
por: Glaspy, J A, et al.
Publicado: (2002)

Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
por: Ots, Pilar Ma Samper, et al.
Publicado: (2008)

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)
por: McMurray, John J.V., et al.
Publicado: (2013)

A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study
por: Akizawa, Tadao, et al.
Publicado: (2016)

Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa
por: Tani, Junya, et al.
Publicado: (2020)

Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial
por: Sinha, Shubhadeep D., et al.
Publicado: (2019)

Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study
por: Asada, Shinji, et al.
Publicado: (2019)

Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO
por: Egrie, J, et al.
Publicado: (2002)

Darbepoetin alfa reduces cell death due to radiocontrast media in human renal proximal tubular cells
por: Andreucci, Michele, et al.
Publicado: (2021)

Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)
por: Nangaku, Masaomi, et al.
Publicado: (2020)

Vitamin D Receptor Activator Use and Cause-specific Death among dialysis Patients: a Nationwide Cohort Study using Coarsened Exact Matching
por: Obi, Yoshitsugu, et al.
Publicado: (2017)

Safety, Tolerability, and Immunogenicity of Prescribed Usage of Darbepoetin-Alfa (Hetero Biopharma) in Patients of Chronic Kidney Disease With Renal Anemia: A Post-Marketing Surveillance Study
por: Sinha, Shubhadeep D, et al.
Publicado: (2021)

An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study
por: Galle, Jan-Christoph, et al.
Publicado: (2012)

Correction to: Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial
por: Sinha, Shubhadeep D., et al.
Publicado: (2019)

Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism
por: Kato, Chihiro, et al.
Publicado: (2020)

Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study
por: Asada, Shinji, et al.
Publicado: (2020)

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
por: Gabrilove, Janice, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_i211gd4ic82e1v3en93v1sm8au